Skip to main content

Lisdexamfetamine Disease Interactions

There are 11 disease interactions with lisdexamfetamine:

Major

Amphetamines (applies to lisdexamfetamine) cardiovascular

Major Potential Hazard, Moderate plausibility. Applicable conditions: Cerebral Vascular Disorder, Cardiovascular Disease, Heart Disease, History - Cerebrovascular Disease, History - Myocardial Infarction, Hyperthyroidism

The use of amphetamines and amphetamine-like drugs is contraindicated in patients with advanced arteriosclerosis, symptomatic or unstable cardio- or cerebrovascular disease, moderate to severe hypertension, or hyperthyroidism. Like other sympathomimetic amines, amphetamines may cause cardiovascular adverse effects such as palpitation, tachycardia, cardiac arrhythmias, and elevation of blood pressure. Rarely, cardiomyopathy manifested as ventricular hypertrophy and/or congestive heart failure has been reported during chronic amphetamine use. In addition, sudden death has been reported in association with amphetamine therapy at usual dosages in children with structural cardiac abnormalities. In general, amphetamines should not be used in patients with structural cardiac abnormalities. If not otherwise contraindicated, therapy with amphetamines should be administered cautiously in patients with a current or past history of cardiovascular or cerebrovascular disease.

References

  1. "Product Information. Fastin (phentermine)." SmithKline Beecham, Philadelphia, PA.
  2. "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.
  3. "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.
  4. Smith HJ, Roche AH, Jausch MF, Herdson PB "Cardiomyopathy associated with amphetamine administration." Am Heart J 91 (1976): 792-7
  5. Gibbs HR "Diet pills and sudden death." N Engl J Med 318 (1988): 1127
  6. Kokkinos J, Levine SR "Possible association of ischemic stroke with phentermine." Stroke 24 (1993): 310-3
  7. Douglas A, Douglas JG, Robertson CE, Munro JF "Plasma phentermine levels, weight loss and side-effects." Int J Obes 7 (1983): 591-5
  8. "Product Information. Prelu-2 (phendimetrazine)" Boehringer-Ingelheim, Ridgefield, CT.
  9. "Product Information. Dexedrine (dextroamphetamine)" SmithKline Beecham, Philadelphia, PA.
  10. "Product Information. Tenuate (diethylpropion)" Aventis Pharmaceuticals, Swiftwater, PA.
  11. "Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.
  12. Ragland AS, Ismail Y, Arsura EL "Myocardial infarction after amphetamine use." Am Heart J 125 (1993): 247-9
  13. "Product Information. Desoxyn (methamphetamine)" Abbott Pharmaceutical, Abbott Park, IL.
  14. Ayres PR "Amphetamine cardiomyopathy [letter]." Ann Intern Med 98 (1983): 110
  15. Bashour TT "Acute myocardial infarction resulting from amphetamine abuse: a spasm- thrombus interplay." Am Heart J 128 (1994): 1237-9
View all 15 references
Major

Amphetamines (applies to lisdexamfetamine) glaucoma

Major Potential Hazard, Moderate plausibility. Applicable conditions: Glaucoma/Intraocular Hypertension

The use of amphetamines and amphetamine-like drugs is contraindicated in patients with narrow-angle glaucoma or anatomically narrow angles. Like other sympathomimetic amines, amphetamines can induce transient mydriasis. In patients with narrow angles, pupillary dilation can provoke an acute attack of angle-closure glaucoma. If possible, these agents should also be avoided in patients with other forms of glaucoma, since mydriasis may occasionally increase intraocular pressure.

References

  1. "Product Information. Prelu-2 (phendimetrazine)" Boehringer-Ingelheim, Ridgefield, CT.
  2. "Product Information. Dexedrine (dextroamphetamine)" SmithKline Beecham, Philadelphia, PA.
  3. "Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.
  4. "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.
  5. "Product Information. Desoxyn (methamphetamine)" Abbott Pharmaceutical, Abbott Park, IL.
  6. "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.
  7. "Product Information. Tenuate (diethylpropion)" Aventis Pharmaceuticals, Swiftwater, PA.
  8. "Product Information. Fastin (phentermine)." SmithKline Beecham, Philadelphia, PA.
View all 8 references
Major

CNS stimulants (applies to lisdexamfetamine) agitation

Major Potential Hazard, Moderate plausibility. Applicable conditions: Neurosis, Psychosis, Anxiety/Stress

The use of central nervous system (CNS) stimulants is contraindicated in patients with marked agitation and/or anxiety, since these symptoms may be aggravated. CNS stimulants may also exacerbate symptoms of behavior disturbance and thought disorder in psychotic patients, particularly children. Therapy with CNS stimulants should be administered cautiously in patients with a history of psychosis or a predisposition to agitated states.

References

  1. "Product Information. Prelu-2 (phendimetrazine)" Boehringer-Ingelheim, Ridgefield, CT.
  2. "Product Information. Dexedrine (dextroamphetamine)" SmithKline Beecham, Philadelphia, PA.
  3. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc, Atlanta, GA.
  4. "Product Information. Fastin (phentermine)." SmithKline Beecham, Philadelphia, PA.
  5. "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.
  6. "Product Information. Desoxyn (methamphetamine)" Abbott Pharmaceutical, Abbott Park, IL.
  7. "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.
  8. "Product Information. Cylert (pemoline)." Abbott Pharmaceutical, Abbott Park, IL.
  9. "Product Information. Tenuate (diethylpropion)" Aventis Pharmaceuticals, Swiftwater, PA.
  10. "Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.
  11. "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals, East Hanover, NJ.
View all 11 references
Major

CNS stimulants (applies to lisdexamfetamine) cardiac disease

Major Potential Hazard, Moderate plausibility. Applicable conditions: Heart Disease, Hyperthyroidism, Hypertension, Pheochromocytoma, Peripheral Arterial Disease

The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc. Sudden death has been reported in adults and children taking CNS stimulant treatment. Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment. A careful assessment of the cardiovascular status should be done in patients being considered for treatment. This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram). Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.

References

  1. "Product Information. Dopram (doxapram)." West-Ward Pharmaceutical Corporation, Eatontown, NJ.
Major

CNS stimulants (applies to lisdexamfetamine) hypertension

Major Potential Hazard, Moderate plausibility.

CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension. Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions. All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.

References

  1. "Product Information. Dopram (doxapram)." West-Ward Pharmaceutical Corporation, Eatontown, NJ.
Major

CNS stimulants (applies to lisdexamfetamine) substance abuse

Major Potential Hazard, Moderate plausibility. Applicable conditions: Alcoholism, Drug Abuse/Dependence

Central nervous system (CNS) stimulants, especially amphetamines, have significant potential for habituation and abuse. Tolerance, psychological dependence and severe social dysfunction can develop after prolonged use. Frank psychotic episodes may also occur in association with chronic intoxication. Therapy with CNS stimulants should be administered cautiously, if at all, in patients with a history of alcohol or substance abuse. The use of amphetamines is considered by manufacturers to be contraindicated in such patients.

References

  1. "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.
  2. "Product Information. Fastin (phentermine)." SmithKline Beecham, Philadelphia, PA.
  3. "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.
  4. "Product Information. Prelu-2 (phendimetrazine)" Boehringer-Ingelheim, Ridgefield, CT.
  5. "Product Information. Dexedrine (dextroamphetamine)" SmithKline Beecham, Philadelphia, PA.
  6. "Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.
  7. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc, Atlanta, GA.
  8. "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals, East Hanover, NJ.
  9. "Product Information. Desoxyn (methamphetamine)" Abbott Pharmaceutical, Abbott Park, IL.
  10. "Product Information. Cylert (pemoline)." Abbott Pharmaceutical, Abbott Park, IL.
  11. "Product Information. Tenuate (diethylpropion)" Aventis Pharmaceuticals, Swiftwater, PA.
View all 11 references
Major

CNS stimulants (applies to lisdexamfetamine) tics

Major Potential Hazard, Moderate plausibility. Applicable conditions: Tic Disorder

Central nervous system (CNS) stimulants have been reported to exacerbate Tourette's syndrome and other motor and phonic tics. Therapy with CNS stimulants, if necessary, should be administered cautiously in patients with tic disorders or family history of Tourette's syndrome. The manufacturers of the CNS stimulants, methylphenidate (racemic) and dexmethylphenidate (the more pharmacologically active d-enantiomer), consider their use to be contraindicated in such patients.

References

  1. "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals, East Hanover, NJ.
  2. "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.
  3. "Product Information. Prelu-2 (phendimetrazine)" Boehringer-Ingelheim, Ridgefield, CT.
  4. "Product Information. Cylert (pemoline)." Abbott Pharmaceutical, Abbott Park, IL.
  5. "Product Information. Dexedrine (dextroamphetamine)" SmithKline Beecham, Philadelphia, PA.
  6. "Product Information. Tenuate (diethylpropion)" Aventis Pharmaceuticals, Swiftwater, PA.
  7. "Product Information. Fastin (phentermine)." SmithKline Beecham, Philadelphia, PA.
  8. "Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.
  9. "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.
  10. "Product Information. Desoxyn (methamphetamine)" Abbott Pharmaceutical, Abbott Park, IL.
  11. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc, Atlanta, GA.
View all 11 references
Moderate

CNS stimulants (applies to lisdexamfetamine) bipolar disorders

Moderate Potential Hazard, Moderate plausibility.

Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder. Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression). Close monitoring is recommended when using these agents in patients with bipolar disorders.

Moderate

CNS stimulants (applies to lisdexamfetamine) psychotic disorders

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Psychosis

Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder. Close monitoring is recommended when using these agents in patients with psychotic disorders.

Moderate

CNS stimulants (applies to lisdexamfetamine) seizure disorders

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Seizures

Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures. These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures. Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures. If seizures appear, therapy should be discontinued.

References

  1. American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
Moderate

Lisdexamfetamine (applies to lisdexamfetamine) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

The dose of lisdexamfetamine should not exceed 50 mg/day in patients with severe renal impairment (GFR 15 to < 30 mL/min/1.73 m2) due to reduced clearance of the drug. The maximum recommended dose in patients with end stage renal disease (GFR < 15 mL/min/1.73 m2) is 30 mg/day. Lisdexamfetamine is not dialyzable.

Lisdexamfetamine drug interactions

There are 332 drug interactions with lisdexamfetamine

Lisdexamfetamine alcohol/food interactions

There are 3 alcohol/food interactions with lisdexamfetamine

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.